Trial Profile
A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Ibuprofen (Primary) ; Lenograstim (Primary) ; Pantoprazole (Primary) ; Plerixafor (Primary)
- Indications Chronic granulomatous disease; Stem cell mobilisation
- Focus Adverse reactions; Therapeutic Use
- Acronyms XCGD-MOBI
- 27 Oct 2022 Planned End Date changed from 1 Aug 2018 to 18 Jul 2023.
- 27 Oct 2022 Planned primary completion date changed from 1 Sep 2017 to 13 Jul 2023.
- 07 Dec 2015 New trial record